Given the availability of human studies of the relatively specific and potent glucagon-like peptide (GLP)-1 receptor antagonist exendin (Ex) \textsuperscript{9-39}, it was just a question of time for the first study of GLP-1 receptor blockade after gastric bypass surgery to appear. In this issue of Diabetes, Salehi et al. (1) report such studies in two groups of individuals previously operated on for obesity with Roux-en-Y gastric bypass (RYGB) surgery: one asymptomatic group and one control group with recurrent hypoglycemia after the operation.

The background is that these operations not only bring about a massive weight loss (reductions in BMI from 52 to 33/32 kg/m\textsuperscript{2} in the current study), but also bring about resolution of type 2 diabetes, if present, in a high percentage (80–90\%) of patients. In the current study, three of twelve individuals in both operated groups had type 2 diabetes before the operation, which was resolved completely in all cases. RYGB was originally conceived as a restrictive and malabsorptive procedure, but actually it is neither. The normal function of the stomach is to retain and process food stuff until allowing a controlled emptying precisely adjusted to the digestive capacity of the proximal intestine. The reservoir is lost after the operation and, in effect, a straight tube is constructed that allows unimpeded passage of ingested nutrients directly to the alimentary limb of the Y-anastomosis and directly onwards to the “common limb,” where nutrients are admixed with digestive secretions and digestion starts. This is nicely illustrated in studies of acetaminophen absorption, which proceeds at a maximal rate immediately upon meal ingestion without the slightest retardation (2). Furthermore, balance studies have documented that there is no malabsorption of macronutrients after RYGB (3).

So what is the mechanism of both the weight loss and the diabetes resolution? The abnormal passage of nutrients to a site some 1.5–2 m more distal to the duodenum clearly poses a dramatic exposure of nutrients to the mucosa there, and this is clearly reflected in a grossly exaggerated secretion of gut hormones (4,5). These include peptide YY (PYY)\textsuperscript{3-36}, a powerful anorexic hormone (6), and GLP-1, a peptide that powerfully inhibits appetite and food intake and, in addition, stimulates insulin secretion (7). While PYY has no effect on insulin secretion, the effects of GLP-1 are sufficiently powerful to allow development of GLP-1 receptor agonists for the treatment of diabetes (8). Clinical studies have clearly supported an association between the exaggerated secretion of these two hormones and the weight loss (3). Regarding diabetes resolution, it was recently reported that a patient with type 2 diabetes who was newly operated on received a test meal either orally (following the bypass) or via a gastrostomy catheter (following the preoperative nutritional pathway) on 2 consecutive days. When fed via the bypass, the patient had normal glucose tolerance, but when fed through the stomach he had diabetes. Bypass feeding was associated with a large insulin response and a grossly exaggerated GLP-1 response; in fact, the two were highly correlated (r = 0.93) (9). In the current study by Salehi et al. (1), meal-infused responses were studied under the conditions of a hyperglycemic clamp (of approximately 14 mmol/L) with or without a high rate, primed infusion of Ex 9–39 (in other studies was demonstrated to block the actions of exogenous GLP-1). After plateau glucose levels were established, a 375-kcal test meal (Ensure) was given, and insulin responses were typically found (12,13).

These observations seem to strongly support the hypothesis that an important part of the antidiabetic effect of RYGB is due to exaggerated secretion of GLP-1, which in turn stimulates insulin secretion (Fig. 1). One can discuss whether the infusion rate of Ex 9–39 and the design of the study allow for a full appreciation of the effects of GLP-1, but at any rate, the difference in insulin responses must reflect the effects of GLP-1 receptor activation. So far, so good. But the picture seems to be more complicated. The study included two groups of operated individuals—one that developed recurrent hypoglycemia, which was also demonstrated during a separate meal tolerance test. Surprisingly, the two groups had almost identical insulin and GLP-1 responses (as well as secretion of GIP, the other incretin hormone from the proximal gut, which is variably influenced by bypass surgery). This, however, is at variance with earlier studies of patients with postbypass hypoglycemia (which typically develops 1–3 years after surgery), where both exaggerated GLP-1 and insulin responses were typically found (12,13). This raises the question of whether the mechanism of the postoperative hypoglycemia can be studied appropriately using the clamp...
approach used here. Obviously, because of the clamp,
hypoglycemia was not present. In the separate meal test, 
10 out of 12 members of the hypoglycemia group did de-
velop hypoglycemia, leading to termination of the experi-
ment. Only two individuals remained toward the end of the  
meal experiment (while all 12 completed the test in the  
asymptomatic group), which means that comparisons be-
tween glucose, insulin, and gut hormone responses (not  
reported) are impossible. Thus, the mechanism of post-
operative hypoglycemia probably deserves further investi-
gation, for instance in experiments with smaller meals where  
hypoglycemia is less dramatic, and where insulin and gut  
hormones responses can be adequately compared. In fact, in  
a recent study of a patient with postoperative hypoglycemia,  
feeding via a gastrostomy catheter eliminated both the ex-
aggerated GLP-1 response—hyperinsulinemia—and the  
hypoglycemia (14).

Another result that is not easily interpreted in terms of  
diabetes resolution after RYGB is the glucagon responses  
to the test meal. Whereas in control subjects, glucagon  
concentrations fell in response to the hyperglycemic clamp  
and did not change much during the test meal, the  
surgical groups showed dramatic and similar elevated  
meal responses that were (in agreement with earlier  
studies [10,15]) increased by Ex 9–39. Similar postprandial  
glucagon increases have been observed in other studies  
(2,12) and are seemingly incompatible with the antidi-
betic effects of RYGB and with the inhibitory effects of  
GLP-1 on glucagon secretion (7). One possibility might be  
that the elevated levels are gut-derived and represent  
N-terminally elongated, biologically inactive forms, e.g.,  
proglucagon 1–61 (16). The processing of proglucagon in  
the L cells may include formation of this molecular form  
(17), which could be pronounced given the dramatic  
overstimulation of the L cells after bypass surgery. Cur-
rently available glucagon assays would not be able to dif-
ferrate between the two molecular forms.

Finally, it is worth noting that Ex 9–39 had effects on  
both insulin secretion and GLP-1, also before meal in-
gestion. This raises the question of whether Ex 9–39 acts  
exclusively as a competitive antagonist or whether it may  
also act as an inverse agonist, inhibiting GLP-1 receptor  
signaling in the absence of GLP-1 (18). This problem needs  
to be addressed when using Ex 9–39 for delineation of  
physiological effects of GLP-1.

A recently published study by Hansen et al. (19) mea-
sured insulin and gut hormone responses to test meals  
delivered either orally or via a gastrostomy catheter early  
after RYGB surgery, but in that study there were no clear  
differences between responses to orally and tube-delivered  
meals, and there was no conspicuous insulin release post-
operatively. This led the authors to question the mecha-
nisms for diabetes resolution outlined above. However, the  
samples in that study were not obtained in the period 20–  
80 min after the meal. Upon inspection of the responses in  
the article by Salehi et al. (1) in this issue of Diabetes and
in the earlier studies cited (2,5,12), it is clear that the hyperinsulinemia and exaggerated GLP-1 responses occur exactly in that interval, which therefore was missed by Hansen et al. (19). Currently, therefore, hypotheses regarding the diabetes resolution after RYGB surgery based on GLP-1 have gained further support from the studies of Salehi et al.

ACKNOWLEDGMENTS
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1 stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308–2314
2. Falkén Y, Hellström PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011;96:2227–2235
3. Zagler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab 2009;35:544–557
4. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780–785
5. Kielgast U, Volund, A, Holst, JJ, Madsbad, S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011;60:1599–1607
6. McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010;95:1851–1855
7. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006;4:223–233
8. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127–136
9. Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 2010;33:375–377
10. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86–93
11. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011;60:1599–1607
12. Patti ME, McMahan G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005;48:2236–2240
13. Patti ME, McMahan G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005;48:2236–2240
14. Baldissera FG, Holst JJ. Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. Diabetologia 1986;29:396–399
15. Serre V, Dolci W, Schaerer E, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 1998;139:4448–4454
16. Hansen EN, Tamboli RA, Isbell JM, et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol 2011;300:G796–G802